Status:
COMPLETED
The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance
Lead Sponsor:
Tropical Medicine Research Institute
Collaborating Sponsors:
London School of Hygiene and Tropical Medicine
World Health Organization
Conditions:
Falciparum Malaria
Antimalarials
Eligibility:
All Genders
2+ years
Brief Summary
The newly introduced antimalarial drug artemether-lumefantrine is currently recommended as second line antimalarial in Sudan. Recurrent infection after treatment with this drug has been associated wit...
Detailed Description
In Sudan the current treatment protocol includes two artemisinin combinations (ACT); artesunate + sulphadoxine/pyrimethamine (AS/SP) as first line and artemether-lumefantrine (AL) as second line. This...
Eligibility Criteria
Inclusion
- Mono-infection with P. falciparum by microscopy.
- Initial parasite density of 1000 to 100,000 asexual parasites/µl.
- Absence of general danger signs or other signs of severe and complicated falciparum malaria according to WHO definitions.
- Informed consent provided by patient or parent/guardian.
Exclusion
- Pregnancy
- Infection with mixed Plasmodium sp.
- Signs of severe malaria or any danger signs
- Refusal to provide consent
Key Trial Info
Start Date :
October 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00440752
Start Date
October 1 2006
End Date
December 1 2006
Last Update
March 26 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tropical Medicine Research Institute
Khartoum, Khartoum State, Sudan, 11111